Health

Kaiser's 1,200-scan trial found AI echo drafts matched clinicians and halved read time

The Permanente Medical Group ran the randomized trial of EchoPrime itself and found the AI drafts matched clinician drafts while cutting cardiologist read time nearly in half. Days later it launched Permanentech, its own vehicle to commercialize clinical AI, so the buy-or-build question just got a benchmark.

Richard TangRichard Tangthree-minute read
Share
An echocardiography machine with a live cardiac ultrasound on its monitor beside an empty exam table in a cardiac imaging room
An echocardiography cart and exam table in a cardiac imaging suite. Kaiser's 1,200-scan trial had cardiologists finalize an AI draft in 274 seconds on average, against 507 seconds with no draft.

The Permanente Medical Group, Kaiser Permanente's 10,000-doctor group, funded and ran the trial itself: 1,200 echocardiograms from 21 Northern California centers, each read by a sonographer, a cardiologist and EchoPrime, an AI model licensed to InVision Medical Technology 1. Blinded cardiologist overreaders made substantial changes to half the AI drafts and half the clinician drafts, meeting the trial's noninferiority bar 1. David Ouyang, the Kaiser Permanente cardiologist behind the model, is now preparing the FDA clearance needed to deploy it in practice 5.

Parity on accuracy, decisive on time

Accuracy is not the money here; seconds are. A cardiologist finalizing a report from an AI draft spent nearly half the time of reading with no draft at all 1. And the AI draft does what no human draft can do for free: it erases the nearly ten minutes a sonographer spends writing the preliminary interpretation before a cardiologist ever looks 1. Echo demand keeps climbing as the population ages while the imaging workforce stays the same size, and Ouyang says that backlog, not accuracy, is what motivated the trial 5.

Any preliminary draft roughly halves the cardiologist's read time

0 sec200 sec400 sec600 secNo draft507 secSonographer draft282 secCardiologist draft276 secAI draft274 sec
Data
Value
No draft507 sec
Sonographer draft282 sec
Cardiologist draft276 sec
AI draft274 sec
Mean seconds a cardiologist spent finalizing one echocardiogram report, by source of the preliminary draft, in the AI ECHO INSIGHT randomized trial of 1,200 echoes at 21 Kaiser Permanente Northern California centers. The AI draft also removes the roughly ten minutes a sonographer spends writing the preliminary interpretation. Source: TCTMD report of AI ECHO INSIGHT, AHA 2026.1

The caveats are the price list

The trial was not powered to show any effect on patient outcomes, the AI was inferior to cardiologists reading alone, and overreaders guessed which interpreter wrote a draft barely better than chance 1. None of that kills the model. It prices it: EchoPrime is validated as a drafting tool whose final read a cardiologist still owns, not a replacement 15.

Models do not travel, validated deployments do

The same week, Kaiser's research division published 49 models that predict pregnancy complications from routine medical records for roughly 443,000 pregnancies, and showed the models lose accuracy when moved to a nationwide dataset until they are locally adapted 26. That is the pattern for clinical AI: models do not travel, validated deployments do.

The value lands with whoever owns the read layer

No listed company sells EchoPrime; it is Cedars-Sinai intellectual property licensed to the private InVision Medical Technology 5. The value lands with whoever holds the read layer: the integrated operator banks a labor line per scan and can cap what it pays vendors, because it has now proven it can trial a vendor's model in its own halls and publish the result 1. Permanentech, the wholly owned innovation company TPMG launched this week to partner with outside AI developers and build physician-created tools, is the hedge on both sides of that trade 34.

The model gets the headline. The validation pipeline gets the margin. Kaiser has just shown it can test the best outside model against its own clinicians, and that it intends to own the pipeline that makes such tests possible.

Get Health by email, free

AI in medicine, pharma and biotech. In our daily email, every weekday.

Reader comments

0 comments

    More in Health

    All in this topic →

    Health

    OpenAI lets clinicians prescribe from ChatGPT through Photon, moving pharmacy choice to patients

    For Evidenced, the healthcare venture firm that bets on U.S. regulatory tailwinds, the launch adds a second engine: market-driven distribution through OpenAI's clinician base. The free window through December 31 is the first adoption test for its portfolio company Photon.

    Health

    Eli Lilly Agreed to Buy Calytrix Bio for Up to $1.5 Billion, Its Latest Deal in a $32 Billion Year

    A $32 billion acquisition year rests on an $11 billion quarterly cash engine, but the deal headlines are "up to" figures and the balance sheet is already thinning. Whose money moves: anyone holding LLY at 31 times forward earnings into December 7 and January.

    Health

    GE HealthCare's manganese MRI agent matched gadolinium, a route past China's rare earths

    About 65 million contrast-enhanced MRI scans a year run on gadolinium, a rare earth whose export China licenses. A manganese substitute that matched the incumbent in GE HealthCare's Phase 2 trial opens a route off that chain for the company's highest-margin segment, if Phase 3 holds.

    Health

    Abridge lost AI scribing to Microsoft and Epic; its next market has a $100 million price from Wolters Kluwer

    Microsoft and Epic took two of every three new AI-scribe dollars this year, and Abridge, which built that market, is selling what comes after the note. The decision-support category it is moving into just got a public price, Wolters Kluwer's $100 million AgileMD deal, and that price is what Abridge's $6.69 billion private mark has to outrun.

    Health

    CMS's CRUSH rule reaches past Medicare into Molina's $42 billion Medicaid book

    The November 18 rout priced the proposal as a UnitedHealth-Humana Medicare bill. Molina is leaving that business, so for it the rule's weight falls on the Medicaid audit duties covering the $42 billion premium book that carries its $9.50 2027 earnings framework.

    Health

    AstraZeneca commits $200 million to Tempus AI through 2031 but can walk away for the shortfall

    A five-year, $200 million renewal from AstraZeneca gives Tempus AI a revenue floor it can book, filed days before a shareholder vote on a stock-funded acquisition, but the contract lets the drugmaker quit early by paying only the shortfall.

    Subscribe to TheInference for free